1800 605-5127
+61 (0)8 8352 7711
Favipiravir, Purified Small Molecule
Only %1 left
Catalog Number
PE-1852
Discontinued
- Product Name Favipiravir, Purified Small Molecule
- Product Description Favipiravir (T-705) is a novel viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5'-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with IC50
- Alternative Names 6-Fluoro-3-hydroxypyrazine-2-carboxamide; CAS 259793-96-9; T-705
- Application(s) Neutralize
- Purity Description >99% (HPLC); NMR (Conforms)
- Purity % > 98%
- Regulatory Status For research use only.
Product Info
- Product Description Favipiravir (T-705) is a novel viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5'-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase (RdRP) activity with IC50
- Application(s) Neutralize
- Application Details Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 _g/ml for the influenza A viruses, from 0.039 to 0.089 _g/ml for the influenza B viruses, and from 0.030 to 0.057 _g/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 _g/ml. [1] In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis. [
- Target Favipiravir
- Target Host Species Species Independent
- Purity Description >99% (HPLC); NMR (Conforms)
- Purity % > 98%
- Format Dry powder; Off-white powder
- Reconstitution Instructions Soluble in DMSO. May be dissolved in DMSO up to 30 mg/mL, or water up to 12 mg/mL.
- Storage Instructions Store desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 1 month. Prevent multiple freeze-thaw cycles.
- Batch Number Please see item label.
- Expiration Date See storage conditions.
- Alternative Names 6-Fluoro-3-hydroxypyrazine-2-carboxamide; CAS 259793-96-9; T-705
- Scientific Background T-705 (Favipiravir) is a broad-spectrum antiviral molecule currently in late stage clinical development for the treatment of influenza virus infection. Although it is believed that T-705 potency is mediated by its ribofuranosyl triphosphate (T-705 RTP) metabolite that could be mutagenic, the exact molecular interaction with the polymerase of influenza A virus (IAVpol) has not been elucidated.
- Shipping Temperature 25°C (ambient)
- UNSPSC CODE 12352401
- Regulatory Status For research use only.
Specifications
-
General References
Y Furuta et al. Antimicrob. Agents Chemother. 2002 46:977
K Takahashi et al. Antivir. Chem. Chemother. 2003 14:235
K Sleeman et al. Antimicrob. Agents Chemother. 2010 54:2517
Y Furuta et al. Antimicrob. Agents Chemother. 2005 49:981
Y Furuta et al. Antiviral Res. 2013 100:446
L Dong et al. Drug Discov.Ther. 2020 14:58
YF Tu et al. Int. J. Mol. Sci. 2020 21:E2657